NCT02112188

Brief Summary

The purpose of the study is to modify a type of counseling called "Individual Meaning Centered Psychotherapy" to meet the needs of Chinese cancer patients. Many cancer patients use counseling or other resources to help cope with the emotional burden of their illnesses. Counseling often helps them cope with cancer by giving them a place to express their feelings. "Meaning-Centered" counseling aims to teach cancer patients how to maintain or even increase a sense of meaning and purpose in their lives, despite cancer.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
84

participants targeted

Target at P50-P75 for all trials

Timeline
10mo left

Started Apr 2014

Longer than P75 for all trials

Geographic Reach
1 country

9 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress94%
Apr 2014Feb 2027

Study Start

First participant enrolled

April 1, 2014

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

April 7, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 11, 2014

Completed
12.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2027

Last Updated

January 14, 2026

Status Verified

January 1, 2026

Enrollment Period

12.9 years

First QC Date

April 7, 2014

Last Update Submit

January 12, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • adapt the Individual Meaning-Centered Psychotherapy (IMCP)

    through formative research, including in-depth interviews, to be culturally and linguistically tailored for Chinese immigrant cancer patients (IMCP-Ch), using the Ecological Validity Model (EVM) of Bernal et al. (3) and the Cultural Adaptation Process (CAP) model of Domenech-Rodriquez and Weiling (1). This addresses existential issues using didactics and experiential exercises and has demonstrated efficacy in reducing existential suffering and improving psychosocial functioning among advanced cancer patients.

    2 years

Study Arms (1)

Chinese patients with advanced cancer

IMCP intervention to be culturally \& linguistically tailored for Chinese cancer patients. This study will be carried out in 3 phases: 1) formative research \& 2) adaptation. For this application we will continue the formative research (phase 1) by conducting 20 to 30 indepth interviews with Chinese immigrants with advanced cancer to inform the adaptation of the intervention. Results of the patient in-depth interviews will inform how to adapt the IMCP process \& session themes to reflect the needs of the community. In the adaptation phase (phase 2) the Breitbart IMCP research team (including Drs. Breitbart, Lichtenthal, \& Applebaum), Drs. Leng, Gany, \& Ms. Huang will discuss a priori adaptations to the intervention. Potential changes to the process \& content will be discussed. Adaptations will be incorporated in a modified IMCP-Ch treatment manual, therapist checklist/outline \& Treatment Integrity Coding Manual. PHASE 3, 4 Conduct feasibility study of IMCP-Ch for Chinese cancer patients.

Behavioral: In-depth Patient InterviewsBehavioral: Adaptation of IMCP for Chinese Immigrant Cancer PatientsBehavioral: Individual Meaning-Centered Psychotherapy for Chinese (IMCP-Ch) (For Phase 3 and Phase 4)

Interventions

Chinese patients with advanced cancer
Chinese patients with advanced cancer

The six sessions will be delivered every or every other week over a span of 6-16 weeks, depending on participant and interventionist availability. Sessions may also be delivered within 2 weeks to accommodate schedules. Sessions will take place via MSK-approved videoconferencing platforms (e.g. Zoom) or by telephone, depending on participant preference. The IMCP-Ch intervention will be delivered via telehealth in Mandarin Chinese by a bilingual interventionist or in English (for bilingual Chinese and English-speaking patients who prefer English) by an English-speaking therapist or through English-to-Mandarin Remote Simultaneous Medical Interpretation (RSMI), depending on participants' preference. All Phase 4 sessions will be digitally audio-recorded and saved to Zoom cloud. Cloud recording will be deleted from Zoom after the files have been uploaded.

Chinese patients with advanced cancer

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Phase I participants will be recruited through MSKCC and referrals provided by Qcc, CCHC, ACS Asian Initiatives, CBWCHC, NYHQ and NYCAAMH and the Cheung and Kan Medical Group. Phase 3 and 4 participants will be recruited through MSKCC and referrals provided by community clinicians/collaborating partners. Flyers (Phase 3, Appendix H) in Chinese announcing the study will be distributed through MSKCC and community organizations and hospitals (e.g., QCC, WCMC, NYP LMH, CCHC, ACS Asian Initiatives, CBWCHC, NYHQ, the Cheung and Kan Medical Group and NYCAAMH).

You may qualify if:

  • Phases 1 and 2:
  • Non-US born;
  • Of Chinese descent;
  • Age 21 years through 80 years;
  • Language spoken: Mandarin and/or English
  • Diagnosis of Stage IV cancer (any type).
  • Phase 3:
  • Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
  • Age 18 or older
  • Of Chinese descent
  • Mandarin-speaking
  • Have an estimated life expectancy of at least 6 months (per self-report or on the MSKCC EMR)
  • Resides in New York State or New Jersey
  • Phase 4:
  • Stage III or IV cancer (per self-report or on the MSKCC EMR). If traditional staging does not apply (i.e. for leukemia), we can allow patient deemed by provider to have poor prognosis/roughly equivalent to Stage III or IV to be referred.
  • +5 more criteria

You may not qualify if:

  • Phases 1 and 2:
  • Presence of cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection. The Chinese version of the Mini Mental State Examination (MMSE) (46) will be used as a cognitive screening tool. Patients with MMSE scores below 20 will be excluded. For English speaking patients we will use the English version of the MMSE.
  • Has a household member who has already participated (or agreed to participate).
  • Phase 3:
  • Previous participation in Phases 1 or 2 of the study
  • Unable/unwilling to use or no access to a telehealth platform (i.e., telephone or videoconference)
  • For participants who express interest in RSMI, unable/unwilling to use Zoom videoconferencing platform
  • Unable or unwilling to commit to up to 16 weeks to complete 6-session intervention and follow-up assessments
  • Major psychiatric illness or cognitive impairment that in the judgment of study investigators or study staff would preclude study participation
  • Patients diagnosed with primary brain tumors (per self-report or on the MSKCC EMR), as they may have difficulty completing the intervention and answering questionnaires
  • Undergoing hematopoietic stem cell transplantation (HSCT) (per self-report or on the MSKCC EMR)
  • Currently in psychotherapeutic treatment (patients being treated with psychotropic medications will not be excluded, as long as they are not in psychotherapy; per self report)
  • Phase 4:
  • Previous participation in Phases 1, 2, or 3 of the study
  • Unable/unwilling to use or no access to the Zoom videoconferencing platform (required for RSMI)
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, 07920, United States

Location

Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities)

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, 10604, United States

Location

City College of New York (Data Collection AND Data Analysis)

New York, New York, 10031, United States

Location

MSK at Ralph Lauren (Limited Protocol Activities)

New York, New York, 10035, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Memorial Sloan Kettering Nassau (Limited Protocol Activities)

Uniondale, New York, 11553, United States

Location

Related Publications (1)

  • Lui F, Gany F, Espinosa A, Riobo C, Chang F, Narang B, Rodriguez A, Gonzalez J, Niu Y, Chen RY, Jiang R, Leng J. INTERPRETing to increase access to PSYcho-oncology care (INTERPRET-PSY) for cancer patients with limited English proficiency: study protocol for a pilot randomized controlled trial. Pilot Feasibility Stud. 2026 Jan 29;12(1):31. doi: 10.1186/s40814-026-01770-5.

Related Links

MeSH Terms

Interventions

Clinical Trials, Phase IV as Topic

Intervention Hierarchy (Ancestors)

Clinical Trials as TopicClinical Studies as TopicEpidemiologic Study CharacteristicsEpidemiologic MethodsInvestigative TechniquesProduct Surveillance, PostmarketingEvaluation Studies as TopicHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Florence Lui, PhD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 7, 2014

First Posted

April 11, 2014

Study Start

April 1, 2014

Primary Completion (Estimated)

February 15, 2027

Study Completion (Estimated)

February 15, 2027

Last Updated

January 14, 2026

Record last verified: 2026-01

Locations